Neoadjuvant and adjuvant treatment of renal cell carcinoma

References

• Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR. Renal cell cancer stage migration: analysis of the national cancer data bases. Cancer113(1), 78–83 (2009).
   Google Scholar
• Sun M, Thuret R, Abdollah F et al. Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur. Urol.59(1), 135–141 (2011).
   PubMed Web of Science ®Google Scholar
• Golimbu M, Tessler A, Joshi P, Al-Askari S, Sperber A, Morales P. Renal cell carcinoma: survival and prognostic factors. Urology27(4), 291–301 (1986).
   PubMed Web of Science ®Google Scholar
• Kim SP, Alt AL, Weight CJ et al. Independent validation of the 2010 American Joint Committee on Cancer TNM classification for renal cell carcinoma: results from a large, single institution cohort. J. Urol.185(6), 2035–2039 (2011).
   PubMed Web of Science ®Google Scholar
• DeVita VT, Lawrence TS, Rosenberg SA, DePinho RA, Weinberg RA. DeVita, Hellman and Rosenberg’s Cancer: Principles and Practice of Oncology. DeVita VT, Lawrence TS, Rosenberg SA, Weinberg RA, Depinho RA (Eds). Lippincott Williams and Wilkins, PA, USA (2011).
   Google Scholar
• Klatte T, Pantuck AJ. Molecular biology of renal cortical tumors. Urol. Clin. North Am.35(4), 573–580 (2008).
   PubMedGoogle Scholar
• Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat. Rev. Urol.7(5), 277–285 (2010).
   PubMed Web of Science ®Google Scholar
• Hudes GR. Targeting mTOR in renal cell carcinoma. Cancer115(Suppl. 10), 2313–2320 (2009).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med.356(2), 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol.27(22), 3584–3590 (2009).
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trial. Lancet370(9605), 2103–2111 (2007).
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg JE et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol.26(33), 5422–5428 (2008).
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM et al. Sorenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med.356(2), 125–134 (2007).
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the Phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol.27(20), 3312–3318 (2009).
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Davis ID, Jardiak J et al. Pazopanib in locally advanced or metastic renal cell carcinoma: results of a randomized Phase III trial. J. Clin. Oncol.28(6), 1061–1068 (2010).
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med.356(22), 2271–2281 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer116(18), 4256–4265 (2010).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled Phase III trial. Lancet372(9637), 449–456 (2008).
   PubMed Web of Science ®Google Scholar
• Leibovich BC, Lohse CM, Crispen PL et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J. Urol.183(4), 1309–1316 (2010).
   PubMed Web of Science ®Google Scholar
• Gudbjartson T, Hardarson S, Petursdottir V, Thoroddsen A, Magnusson J, Einarsson GV. Histological subtyping and nuclear grading of renal cell carcinoma and their implications for survival: a retrospective nation-wide study of 629 patients. Eur. Urol.48(4), 593–600 (2005).
   PubMedGoogle Scholar
• Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am. J. Surg. Pathol.27(5), 612–624 (2003).
   PubMed Web of Science ®Google Scholar
• dePeralta-Venturina M, Amin M, Tamboli P et al. Sarcomotoid differentiation in renal cell carcinoma. Am. J. Surg. Pathol.25(3), 275–284 (2001).
   PubMedGoogle Scholar
• Flanigan RC, Polcari AJ, Hugen CM. Prognostic variables and nomograms for renal cell carcinoma. Int. J. Urol.18(1), 20–31 (2011).
   PubMed Web of Science ®Google Scholar
• Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J. Urol.166(1), 63–67 (2001).
   PubMed Web of Science ®Google Scholar
• Sorbellini M, Kattan MW, Snyder ME et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J. Urol.173(1), 48–51 (2005).
   PubMed Web of Science ®Google Scholar
• Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J. Urol.168(6), 2395–2400 (2001).
   Google Scholar
• Zisman A, Pantuck AJ, Dorey F et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J. Clin. Oncol.19(6), 1649–1657 (2001).
   PubMed Web of Science ®Google Scholar
• Zisman A, Pantuck AJ, Wieder J et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J. Clin. Oncol.20(23), 4559–4566 (2002).
   PubMed Web of Science ®Google Scholar
• Leibovich BC, Blute ML, Cheville JC et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma. Cancer97(7), 1663–1671 (2003).
   PubMed Web of Science ®Google Scholar
• Karakiewicz PI, Briganti A, Chun FKH et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J. Clin. Oncol.25(11), 1316–1322 (2007).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Muui LM et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N. Engl. J. Med.316(15), 889–897 (1987).
   PubMed Web of Science ®Google Scholar
• Fisher RI, Coltman CA, Doroshow JH et al. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. Ann. Intern. Med.108(5), 518–523 (1988).
   PubMed Web of Science ®Google Scholar
• Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 paitents with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol.13(3), 688–696 (1995).
   PubMed Web of Science ®Google Scholar
• Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol.21(16), 3127–3132 (2003).
   PubMed Web of Science ®Google Scholar
• McDermott DF, Regan MM, Clark JI et al. Randomized Phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol.23(1), 133–141 (2005).
   PubMed Web of Science ®Google Scholar
• Klapper J, Downey SG, Smith FO et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma. Cancer113(2), 293–301 (2008).
   PubMed Web of Science ®Google Scholar
• Pizzocaro G, Piva L, Colavita M et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J. Clin. Oncol.19(2), 425–431 (2001).
   PubMed Web of Science ®Google Scholar
• Messing E, Manola J, Wilding G et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J. Clin. Oncol.21(7), 1214–1222 (2003).
   PubMed Web of Science ®Google Scholar
• Clark JI, Atkins MB, Urba WJ et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a Cytokine Working Group randomized trial. J. Clin. Oncol.21(16), 3133–3140 (2003).
   PubMed Web of Science ®Google Scholar
• Passalacqua R, Buzio C, Buti S et al. Adjuvant low-dose interleukin-2 plus interon-alpha in operable renal cell cancer. A Phase III, randomized, multicenter independent trial of the Italian Oncology Group for Clinical Research(GOIRC). J. Clin. Oncol.25(18S), (2007).
   PubMedGoogle Scholar
• Atzpodien J, Schmitt E, Gertenbach U et al. Adjuvant treatment with interleukin-2 and interferon alpha2 based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br. J. Cancer92, 843–846 (2005).
   PubMed Web of Science ®Google Scholar
• Aitchison M, Bray C, Van Poppel H et al. Final results from an EORTC(GU Group)/NCRI randomized Phase III trial of adjuvant interleukin-2, interferon alpha, and 5-fluorouracil in patients with a high risk of relapse after nephrectomy for renal cell carcinoma (RCC). J. Clin. Oncol.29 (2011) (Abstract 4505).
   Google Scholar
• Pizzocaro G, Piva L, Fronzo GD et al. Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study. J. Urol.138, 1379–1381 (1987).
   PubMed Web of Science ®Google Scholar
• Naito S, Kumazawa J, Omoto T et al. Postoperative UFT adjuvant and the risk factors for recurrence in renal cell carcinoma: a long-term follow-up study. Int. J. Urol.4(1), 8–12 (1997).
   PubMedGoogle Scholar
• Margulis V, Matin SF, Tannir N et al. Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma. Urology73, 337–341 (2009).
   PubMedGoogle Scholar
• Galligioni E, Quaia M, Nerlo A et al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette–Guerin. Cancer77(12), 2560–2566 (1996).
   PubMed Web of Science ®Google Scholar
• Jocham D, Richter A, Hoffmann L et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial. Lancet363(9409), 594–599 (2004).
   PubMed Web of Science ®Google Scholar
• Scherr AJ, Lima JPS, Sasse EC, Lima CS, Sasse AD. Adjuvant therapy for locally advanced renal cell cancer: a systematic review with meta-analysis. BMC Cancer11, 115 (2011).
   PubMedGoogle Scholar
• Fishman M, Antonia S. Specific antitumour vaccine for renal cancer. Lancet363(9409), 583–584 (2004).
   PubMedGoogle Scholar
• Wood C, Srivastava P, Bukowski R et al. An adjuvant autologous therapeutic vaccine (HSPPC-96;vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised Phase III trial. Lancet372(9633), 145–154 (2008).
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs3(1), 76–99 (2011).
   PubMed Web of Science ®Google Scholar
• Wood C, Srivastava P, Lacombe L et al. Survival update from a multicenter, randomized, Phase III trial of vitespin versus observation as adjuvant therapy for renal cell carcinoma in patients at high risk of recurrence. J. Clin. Oncol.27(Suppl.), 15s (2009) (Abstract 3009).
   Web of Science ®Google Scholar
• Shuch B, Li Z, Belldegrun AS. Carbonic anhydrase IX and renal cell carcinoma: prognosis, response to systemic therapy, and future vaccine strategies. Br. J. Urol. Int.101(Suppl. 4), 25–30 (2008).
   Google Scholar
• Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl. J. Med.345(23), 1655–1659 (2001).
   PubMed Web of Science ®Google Scholar
• Mickisch GHJ, Garin A, Poppel HV, Prijck LD, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet358(9286), 966–970 (2001).
   PubMed Web of Science ®Google Scholar
• Flanigan RC, Mickisch G, Sylvester R, Tangen C, Poppel HV, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J. Urol.171, 1071–1076 (2004).
   PubMed Web of Science ®Google Scholar
• Fallick ML, Mcdermott DF, LaRock D, Long JP, Atkins MB. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J. Urol.158(5), 1691–1695 (1997).
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Xie W, Kollmannsberger C et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J. Urol.185(1), 60–65 (2011).
   PubMed Web of Science ®Google Scholar
• Szczylik C, Porta C, Bracarda S et al. Sunitinib in patients with or without prior nephrectomy (Nx) in an expanded access trial of metastatic renal cell carcinoma. J. Clin. Oncol.26(Suppl.), (2008) (Abstract 5124).
   Google Scholar
• Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol.20(1), 289–296 (2002).
   PubMed Web of Science ®Google Scholar
• Heng DYC, Xie W, Regan MM et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large multicenter study. J. Clin. Oncol.27(34), 5794–5799 (2009).
   PubMed Web of Science ®Google Scholar
• van der Veldt AA, Meijerink MR, van den Eertwegh AJ. Sunitinib for treatment of advanced renal cell cancer: primary tumour response. Clin. Cancer Res.14(8), 2431–2436 (2008).
   PubMed Web of Science ®Google Scholar
• Thomas AA, Rini BI, Lane BR et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J. Urol.181(2), 518–523 (2009).
   PubMed Web of Science ®Google Scholar
• Abel EJ, Culp SH, Tannir NM, Matin SF, Tamboli P. Primary tumour response to targeted agents in patients with metastatic renal cell carcinoma. Eur. Urol.59(1), 10–15 (2011).
   PubMed Web of Science ®Google Scholar
• Abel EJ, Culp SH, Tannir NM, Tamboli P, Matin SF, Wood CG. Early primary tumor size reduction is an independent predictor of improved overall survial in metastatic renal cell carcinoma patients treated with sunitinib. Eur. Urol.60(6), 1273–1279 (2011).
   PubMed Web of Science ®Google Scholar
• Karakiewicz P, Suardi N, Jeldres C. Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur. Urol.53(4), 845–848 (2008).
   PubMed Web of Science ®Google Scholar
• Cost NG, Delacroix SE, Sleeper JP, Smith PJ. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval thrombus. Eur. Urol.59, 912–918 (2011).
   PubMed Web of Science ®Google Scholar
• Bose D, Meric-Bernstam F, Hofstetter W, Reardon DA, Flaherty KT, Ellis LM. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol.11(4), 373–382 (2010).
   PubMed Web of Science ®Google Scholar
• Margulis V, Matin SF, Tannir N, Tamboli P. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J. Urol.180(1), 94–98 (2008).
   PubMed Web of Science ®Google Scholar
• Thomas AA, Rini BI, Stephenson AJ, Garcia JA. Surgical resection of renal cell carcinoma after targeted therapy. J. Urol.182(3), 881–886 (2009).
   PubMed Web of Science ®Google Scholar
• Chapin BF, Delacroix SE, Culp SH, Gonzalez G, Wood CG. Postoperative complications from cytoredutive nephrectomy after neoadjuvant targeted therapy for metastatic renal cell carcinoma. J. Clin. Oncol.29(Suppl. 7), (2011) (Abstract 300).
   Google Scholar
• Jonasch E, Wood CG, Matin SF et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J. Clin. Oncol.27(25), 4076–4081 (2009).
   PubMed Web of Science ®Google Scholar
• Cowey CL, Amin C, Pruthi RS, Wallen EM. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J. Clin. Oncol.28(9), 1502–1507 (2010).
   PubMed Web of Science ®Google Scholar
• Hellenthal NJ, Underwood W, Penetrante R et al. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J. Urol.184(3), 859–864 (2010).
   PubMed Web of Science ®Google Scholar
• Powles T, Blank C, Chowdhury S et al. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. Eur. Urol.60(3), 448–454 (2011).
   PubMed Web of Science ®Google Scholar
• Bukowski R, Kabbinavar FF, Figlin RA et al. Randomized Phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell carcinoma. J. Clin. Oncol.25(29), 4536–4541 (2007).
   PubMed Web of Science ®Google Scholar
• Oosterwijk E, Rathmell WK, Junker K et al. Basic research in kidney cancer. Eur. Urol.60(4), 622–633 (2011).
   PubMed Web of Science ®Google Scholar